乳腺癌患者芳香化酶抑制剂治疗期间症状群及影响因素分析  

Analysis on the symptom clusters and influencing factors among breast cancer patients during aromatase inhibitors treatment

作　　者：文翠菊[1] 王玥妮[1] 孙红娟[1] 徐京燕 于新颖[1] Wen Cuiju;Wang Yueni;Sun Hongjuan;Xu Jingyan;Yu Xinying(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Breast Cancer Prevention and Treatment Center,Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺癌预防治疗中心恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《中国实用护理杂志》2022年第2期132-139,共8页Chinese Journal of Practical Nursing

摘　　要：目的了解乳腺癌患者在接受芳香化酶抑制剂治疗期间的症状群及影响因素, 为开展症状群干预提供理论依据。方法采用便利取样方法, 于2020年4月至2021年1月, 采用一般情况调查表、M.D. Anderson症状量表、综合性医院焦虑抑郁量表, 对就诊于北京大学肿瘤医院253例乳腺癌患者进行横断面调查。采用主成分分析提炼症状群, 多元线性回归分析影响因素。结果乳腺癌患者在接受芳香化酶抑制剂治疗期间存在3组症状群:病感症状群、治疗相关-心理症状群、消化系统症状群, 发生率依次为49.4%(125/253)、45.1%(114/253)、22.5%(57/253), 严重程度中位得分依次为2.80、2.00、0.67分。多元线性回归分析显示, 焦虑、文化程度为病感症状群的影响因素(β=0.25、-0.25, 均P<0.05), 焦虑、抑郁、文化程度为治疗相关-心理症状群的影响因素(β=0.34、0.20、-0.16, 均P<0.05), 焦虑、抑郁、化疗史为消化系统症状群的影响因素(β=0.17、0.18、-0.13, 均P<0.05)。结论乳腺癌患者在芳香化酶抑制剂治疗期间受多组症状群的困扰, 护理人员可从改善患者的心理状态、参考患者文化程度及既往治疗方式制订个体化症状群管理方案等方面, 改善患者的症状群。Objective To investigate the symptom clusters and influencing factors among breast cancer patients receiving aromatase inhibitor treatment and to provide a theoretical basis for the symptom clusters management.Methods From April 2020 to January 2021,253 breast cancer patients were recruited in Peking University Cancer Hospital by convenient sampling method.All the patients were cross-sectional investigated by the demographic and clinical characteristics questionnaire,the M.D.Anderson Symptom Inventory,the Hospital Anxiety and Depression Scale.The principal component analysis was used to extract the symptom clusters and the multiple linear regression was used to analyze the risk factors.Results During the period of breast cancer patients receiving aromatase inhibitor treatment,three symptom clusters were identified:sick symptom cluster,treatment related-psychological symptom cluster,digestive symptoms cluster.The prevalence of the three symptom clusters was 49.4%(125/253),45.1%(114/253),22.5%(57/253),respectively.The median severity of the three symptom clusters was 2.80,2.00,0.67,respectively.Multiple linear regression analysis showed that anxiety and education level were the influencing factors of sick symptom cluster(β=0.25,-0.25,all P<0.05),anxiety,depression and educational level were the influencing factors of treatment related-psychological symptom cluster(β=0.34,0.20,-0.16,all P<0.05),anxiety,depression and chemotherapy history were the influencing factors of digestive symptom cluster(β=0.17,0.18,-0.13,all P<0.05).Conclusions Breast cancer patients with aromatase inhibitor treatment are affected by symptom clusters.In order to relieve the symptom clusters,we need pay attention to the mentation,the education level and prerious treatment of the patients.

关 键 词：乳腺肿瘤 芳香化酶抑制剂 内分泌治疗 症状群 影响因素 

分 类 号：R473.73[医药卫生—护理学]